Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -88.33% | -21.09% | 158.66% | 113.26% | 82.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.33% | -21.09% | 158.66% | 113.26% | 82.50% |
| Cost of Revenue | -32.56% | -58.47% | -67.66% | -78.18% | -82.71% |
| Gross Profit | -92.14% | -13.18% | 360.19% | 390.65% | 426.26% |
| SG&A Expenses | 23.90% | -5.64% | -26.90% | -40.72% | -48.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1,489.24% | -914.60% | -21.80% | 47.37% | 62.91% |
| Total Operating Expenses | -78.30% | -43.19% | -15.45% | -28.50% | -37.21% |
| Operating Income | 77.98% | 43.61% | 17.05% | 29.92% | 38.49% |
| Income Before Tax | 119.62% | 61.18% | 16.87% | 25.65% | 31.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 119.62% | 61.00% | 16.19% | 25.07% | 31.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 119.62% | 61.00% | 16.19% | 25.07% | 31.05% |
| EBIT | 77.98% | 43.61% | 17.05% | 29.92% | 38.49% |
| EBITDA | 81.05% | 44.98% | 17.58% | 30.27% | 38.84% |
| EPS Basic | 114.70% | 63.87% | 33.24% | 49.16% | 58.01% |
| Normalized Basic EPS | 74.01% | 49.02% | 33.87% | 53.57% | 63.59% |
| EPS Diluted | 103.93% | 59.86% | 33.24% | 49.16% | 58.01% |
| Normalized Diluted EPS | 68.69% | 47.05% | 33.87% | 53.57% | 63.59% |
| Average Basic Shares Outstanding | 2.00% | 8.52% | 16.20% | 38.51% | 64.01% |
| Average Diluted Shares Outstanding | 10.31% | 13.02% | 16.20% | 38.51% | 64.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |